论文部分内容阅读
目的]初步比较NP和MVP方案对晚期非小细胞肺癌(NSCLC)的疗效和不良反应。[方法]45例Ⅲ期或Ⅳ期NSCLC患者随机分为A组和B组 ,A组应用NP(去甲长春花碱 +顺铂)方案化疗 ,B组应用MVP(丝裂霉素 +长春花碱酰胺 +顺铂)方案化疗 ,至少连用2周期后评价疗效和不良反应。[结果]两组均无完全缓解病例 ,A组有效率为45 5 %(10/22) ,B组35 0 %(7/20) ,差异无显著性(P>0 05)。其中对腺癌有效率A组为53 3 %(8/15) ,B组为35 7%(4/14)。A组静脉炎发生率为27 3 %(6/22) ,B组为0(P<0 05) ;其它不良反应两组均相似。[结论]NP方案为治疗晚期NSCLC较为有效和安全的化疗方案。
Objectives: To compare the efficacy and adverse effects of NP and MVP regimens on advanced non-small cell lung cancer (NSCLC). [Methods] Forty-five patients with stage III or IV NSCLC were randomly divided into group A and group B. Group A was treated with NP (neprobirbine + cisplatin) chemotherapy, and group B was treated with MVP (mitomycin + vinca The basic amide + cisplatin regimen was used to evaluate efficacy and adverse reactions after at least 2 cycles. [Results] There was no complete remission in both groups. The effective rate was 45.5% (10/22) in group A and 35.00% (7/20) in group B. There was no significant difference (P>0.05). The effective rate for adenocarcinoma was 53. 3% (8/15) in group A and 35.7% (4/14) in group B. The incidence of phlebitis in group A was 273% (6/22) and 0 in group B (P < 0 05). Other adverse reactions were similar in both groups. [Conclusion] NP regimen is a more effective and safe chemotherapy regimen for advanced NSCLC.